SABRATEK TAILORING SEAMLESS MULTI-THERAPY INFUSION SYSTEM SALES GROWTH STRATEGY TO ALTERNATE-SITE MARKET; COMPANY EXPECTS TO NET $27.1 MIL. IN PUBLIC OFFERING
This article was originally published in The Gray Sheet
Executive SummarySabratek Corporation is hoping that its products to facilitate the treatment of patients in alternate-site settings will deliver a seamless revenue stream for the firm. To address the need for "cost-effective movement of patients along the continuum of alternate-site care," the company has developed the Seamless Delivery System of "software based infusion devices and related interactive information system," the firm says in a preliminary prospectus for an initial public offering.
You may also be interested in...
Can shaving ever be “friction free”? Not according to Procter & Gamble, which challenged in a complaint to the UK Advertising Standards Authority a claim made by a British cosmetics firm FFS that it provided a “friction free” shaving experience for women via its subscription razor service.
Work has started on UK-only regulations for the medtech and medicines sectors, to ensure that the regulatory framework not only functions but can also react swiftly to needs after the UK leaves the EU. This article is part two of two.